Proteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease

Shijie Wang a, Kyoko Kojima b, James A. Mobley b, Andrew B. West a,⁎

a Center for Neurodegeneration and Neurotherapeutics, Duke University, Durham, NC, USA
b Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA

A R T I C L E   I N F O
Article history:
Received 13 February 2019
Received in revised form 13 June 2019
Available online 20 June 2019

Keywords:
Biomarkers
Neurodegeneration
Extracellular vesicles
Parkinson’s disease
Alzheimer’s disease

A B S T R A C T
Background: Extracellular vesicles (EVs) harbor thousands of proteins that hold promise for biomarker development. Usually difficult to purify, EVs in urine are relatively easily obtained and have demonstrated efficacy for kidney disease prediction. Herein, we further characterize the proteome of urinary EVs to explore the potential for biomarkers unrelated to kidney dysfunction, focusing on Parkinson’s disease (PD).

Methods: Using a quantitative mass spectrometry approach, we measured urinary EV proteins from a discovery cohort of 50 subjects. EVs in urine were classified into subgroups and EV proteins were ranked by abundance and variability over time. Enriched pathways and ontologies in stable EV proteins were identified and proteins that predict PD were further measured in a cohort of 108 subjects.

Findings: Hundreds of commonly expressed urinary EV proteins with stable expression over time were distinguished from proteins with high variability. Bioinformatic analyses reveal a striking enrichment of endolysosomal proteins linked to Parkinson’s, Alzheimer’s, and Huntington’s disease. Tissue and biofluid enrichment analyses show broad representation of EVs from across the body without bias towards kidney or urine proteins. Among the proteins linked to neurological diseases, SNAP23 and calbindin were the most elevated in PD and were further measured.

Interpretation: Urinary EVs are an underutilized but highly accessible resource for biomarker discovery with particular promise for neurological diseases like PD.

© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Extracellular vesicles (EVs) are a subset of small vesicles (40–200 nm) derived from the endolysosomal system and released into biofluids by almost all cell types. EVs play a role in cell-cell communication and are involved in several diseases [1–3]. Recent studies demonstrate EVs mediating some types of immunological responses [4–6], cancer progression and metastasis [7–11], blood coagulation [12,13], and neurodegenerative diseases [1,3,14,15]. Further, emerging studies demonstrate that EVs, especially intraluminal vesicles from multivesicular bodies (i.e., exosomes), can readily cross the blood brain barrier and access tissues throughout the body [16–18]. The specific sources and relative contributions of different types of cells through the body to the EV pool in different biofluids remains almost completely unknown.

Compared to proteins and nucleic acids not enveloped in lipid bilayers in the extracellular space, EVs shelter biomolecules from external nuclease, proteases, and other degradative enzymes. EVs in biofluids can be enriched with little bias using ultracentrifugation or size exclusion approaches [19,20]. Thousands of proteins not usually secreted through canonical pathways have been observed in proteomic studies in purified EV fractions [21–24]. Because of the stability of EV proteins in biofluids and diversity in proteomic composition, EVs are under evaluation for biomarker development for application in diagnostic and prognostic approaches in numerous diseases [19,24,25].

While EVs are ubiquitous in biofluids, they are also in very low relative concentration compared to more abundant secreted proteins such as immunoglobulins, albumins, and lipoproteins. Higher volume collections of biofluids required for reliable measurement of EV proteins in cerebrospinal fluid, saliva, and plasma present technical challenges in routine clinical settings for biomarker discovery. In contrast, urine can be routinely collected in the hundreds of milliliters in a non-invasive manner without risk. Urinary EV proteins have shown strong promise for kidney diseases including Gitelman syndrome, familial renal hypermagnesemia, urogenital cancers, and acute kidney injury [20,26–28].

Given the polydispersity and recently recognized ability of some EVs to spread throughout the body, herein, we systematically evaluated the
Research in context

Evidence before this study

Urinary extracellular vesicles (EVs) have been studied primarily in kidney disease, with the underlying assumption that the majority of the EV pool is composed of extracellular vesicles secreted from kidney cells. Recent experiments demonstrate that EVs have broad access across the body in biofluids and that most, if not all, cells secrete different kinds of EVs. Although thousands of proteins have previously been detected by mass spectrometry in urinary EVs, there have been few attempts to measure urinary EV protein relative abundance, variability over time, and overall potential to better understand disorders unrelated to kidney dysfunction.

Added value of this study

Herein we characterize urinary EVs proteomes obtained from specimens biobanked under the auspices of the Parkinson’s Disease Biomarker Program in clinically well-characterized subjects that lack kidney disease. Bioinformatic and statistical approaches demonstrate that urinary EVs harbor a very stable set of proteins commonly expressed among different subjects that are enriched in proteins associated with neurological diseases. In demonstrating the potential of this source of proteins for biomarkers of possible utility in neurological diseases, we demonstrate that two proteins in urinary EVs, calbindin and SNAP23, may be useful for predicting PD.

Implications of all the available evidence

Our findings warrant the collection and biobanking of urine in suitable quantities for EV recovery in clinical studies that involve neurological disorders, especially neurodegenerative diseases, for discovery and validation of biomarkers important in disease. Further, calbindin and SNAP23 may be prioritized for measurements in EVs isolated from PD cases in longitudinal collections and different biofluids to explore the potential of these two proteins in predicting PD susceptibility and progression.

proteomic composition in urinary EVs collected in several well-characterized clinical cohorts to understand variability over time and differences in disease states unrelated to kidney dysfunction. We identified urinary EV proteins that vary little between individuals over time, as well as proteins that are greatly different in groups and change dramatically over time. Unbiased bioinformatics analysis reveals enrichment in neurological disease-linked proteins, but not kidney-disease-associated proteins, consistent with the polydispersity and multi-organ representation of urinary EV pools. As a case study, we identified several proteins with biomarker potential in a neurological disease, Parkinson’s disease (PD), unrelated to kidney disease. Overall these results show that urinary EVs may have broad biomarker potential in numerous diseases and may be an underutilized resource in clinical research.

2. Materials and methods

2.1. Clinical samples

Biobanked urine and blood was obtained from the Movement Disorder Clinic at the University of Alabama at Birmingham enrolled in the Parkinson’s Disease Biomarker Program [29]. All protocols were approved by an institutional review board. A discovery cohort for this study was collected in 2014 included 50 participants (28 PD and 22 neurologically normal controls). An independent replication cohort was collected in 2015 and 2016 and included 108 participants (57 PD and 51 healthy controls). All samples were coded with unique identifiers and group identification was assigned after final data curation. Demographic information for both cohorts is listed in Supplemental Tables 1 and 2.

All participants were genotyped (NeuroX array) to screen for known pathogenic mutations for neurological diseases. For all subjects included in the study, medical records were evaluated for a lack of kidney disease, glomerular filtration rates were measured from blood creatinine levels and confirmed as normal. Clinical urinalysis was confirmed normal in all subjects. Clinical data (Supplemental Tables 1 and 2) were collected during the same visit as biospecimen deposition.

2.2. Extracellular vesicle (EV) isolation

~80 mL of urine samples previously biobanked in two 50 mL polypropylene centrifuge tubes (Corning orange-caps) were quick-thawed from −80 °C storage with a shaking 42 °C water bath and placed on ice immediately after thawing. Samples were centrifuged at 10,000 × g for 30 min at 4 °C and supernatant was transferred and then centrifuged at 100,000 × g for 1 h at 4 °C. Resultant EV pellets were washed in 1 mL PBS and centrifuge a final time at 100,000 × g for 1 h at 4 °C. Representative EV isolations and analyses are given in Supplemental Fig. 1a.

2.3. Single-particle tracking and light scattering

Some urine EV pellets were re-suspended in 1 mL phosphate-buffered saline (PBS) after washing and analyzed using Nanosight NS300 single particle tracking. Representative vesicle size and concentrations given were recorded over five tracking runs, 60 s per run.

2.4. Mass spectrometry

Urinary EV pellets resultant from ~40 mL of urine were reconstituted in 400 μL of M-PER Mammalian Protein Extraction Buffer (Thermo) supplemented with 1× Halt Protease Inhibitors (Thermo) and sonicated in an ultrasonic water bath for 15 min. Lysates were exchanged into ~40 μL of 100 mM triethylammonium bicarbonate using Amicon Ultra-0.5, 3 k columns (Millipore). Resultant lysates were quantified using EziQ (Invitrogen) and ~10 μg of protein per sample were diluted in 35 μL of LDS sample buffer (Invitrogen). Proteins were reduced with addition of 5 mM dithiothreitol (DTT) and denatured at 70 °C for 10 min prior to loading into NuPAGE 10% Bis-Tris gels (Invitrogen), with electrophoresis of samples to maximum ~1 cm from the wells. Gels were stained overnight with Colloidal Blue dye (Invitrogen) and following destaining each lane was excised and equilibrated into 100 mM ammonium bicarbonate (AmBc) with digestion overnight with Trypsin gold, Mass Spectrometry Grade (Promega). Peptides were finally reconstituted into 0.1% formic acid to a concentration of 0.1 μg μL⁻¹.

For the discovery cohort (see Supplemental Table 1), peptides were injected into a 1260 Infinity nHPLC (Agilent) with separation from a Jupiter C-18 column, 300 A, 5 μm, Phenomenex) in line with a LTQ XL ion trap mass spectrometer, or for the time-course study, peptides injected into a Thermo Orbitrap Velos Pro (Thermo), both equipped with a nanoelectrospray source (Thermo). All fragmentation data were collected in CID mode. The nHPLC was configured with binary mobile phases that included solvent A (0.1% formic acid), and solvent B (0.1% formic acid, 85% acetonitrile) as follows; 10 min at 5% B, 180 min (LTQ XL) or 90 min (Orbitrap) @ 5%–40%B (linear: 0.5 mL/min, analyze), 5 min @ 70%B (2 μL/min, wash), 10 min @ 0%B (2 μL/min, equilibrate).

The LTQ XL operated in data-dependent triple play mode, with a survey scan range of 300-1200 m/z, followed by a zoom scan for charge state determination, and an MS2 scan, both carried out with 2.0 da isolation widths on the three most intense ions. Data were collected in
were then normalized between samples [36]. ProteomeXchange Consortium via the PRIDE [37,38] partner repository cohort mass spectrometry proteomics data have been deposited to the each protein [34,35], and when relevant, spectral count abundances descibed, which compares the number of MS/MS spectra assigned to across experiments were then performed via spectral counting as de-

The longitudinal mass spectrometry peptide identifications were filtered using Bio Inquire, the discovery cohort mass spectrometry peptide identifications were filtered using Scaffold (Protein Sciences). For both programs, the analysis was performed as described before [30]. In short, peptides were filtered and quantified using ProteoIQ (Premierbiosoft, Palo Alto, CA). Filter cut-offs were set with charge state of ≥2+ and minimum peptide length of 6 amino acids with no MH + 1 charge state, with peptide probabilities of ~80% C.I., and with the number of peptides per protein two or more. Protein probabilities were set to a > 99.0% C.I. with FDR < 1.0 [31–33]. Relative quantification across experiments were then performed via spectral counting as described, which compares the number of MS/MS spectra assigned to each protein [34,35], and when relevant, spectral count abundances were then normalized between samples [36].

The longitudinal mass spectrometry proteomics data have been de-

2.5. Cryo-EM

EVs were resuspended in water and applied to Quantifoil holey film (Quantifoil MicroTools, Jena, Germany) and frozen using an FEI Vitrobot. The samples were observed in an FEI Tecnai F20 200 kV field-emission gun microscope equipped with a high-sensitivity Gatan Ultrascan 4000 CCD camera.

2.6. Quantitative immunobLOTS

EV pellets were lysed in 100 μL of 1 × Lamelli buffer (2% SDS, 10% glycerol, 120 mM Tris pH 6.8, 40 mM NaF) freshly supplemented with 50 mg mL−1 DTT. A pool sample was generated by combining 10% w/v of each sample and included in each analytical run and replicate as an internal normalization control. Samples were electrophoresed on 4–20% TGX gradient gels (BioRad) and transferred onto PVDF membranes. Membranes were blocked using LI-COR blocking buffer (LI-COR) for 1 h at room temperature and then cut in half at a ~37 kDa mark. Signals were measured using the LI-COR system with all protein abundance normalized to pool samples between runs. Primary monoclonal antibodies were Hsc70 (StressMarq Bioscience Inc., #SMC-104A/B), SNAP23 (Santa Cruz, #sc-166,244), and Calbinbin antibody (Cell Signaling, #13176). All primary antibodies were used at 1:1000 dilutions in LICOR blocking buffer. IRDye 800CW Donkey anti Mouse IgG (H + L) secondary antibodies (LI-COR, #926–32,212) and IRDye 680LT Donkey anti Rabbit IgG (H + L) secondary antibodies (LI-COR, #926–68,023) were both used at 1:20,000 dilutions in LIORC blocking buffer. For stain-free whole protein detection, EV pellets were lysed and electrophoresed on 4–20% Mini-PROTEAN TGX stain-free gradient gels (Bio-Rad). Fluorescent signals were UV-induced for 5 min and detected using Chemi-Doc imaging systems (Bio-Rad). Signals were quantified in ImageLab using default settings.

2.7. Statistical analysis

Student 2-tailed t-test or Mann-Whitney tests were used for two-group comparisons. P values resulting from protein data were analyzed using limma-moderated t-statistics and Bonferroni-corrected with signif-

3. Results

3.1. Identification of distinct subclasses of urinary extracellular vesicles

Using a differential ultra-centrifugation approach to access the extracellular vesicle (EVs) pool in urine from biobanked human urine samples (Fig. 1a), we first characterized the samples using single-nanoparticle tracking. Two distinct and abundant EV populations emerge in the 30–70 nm range as well as larger vesicles that peak in rel-

3.2. Urinary EV proteins link to neurological disease

Early studies with urinary EVs presume the major source of the ves-

S. Wang et al. / EBioMedicine 45 (2019) 351–361

353
Table 1). Participants with and without PD were matched for sex, age, height, weight, and biobanked urine was collected between 8 AM and 10 AM. A shotgun proteomic evaluation of EV pellets from these fifty samples identified the thousand most abundant proteins in EVs based on a label-free normalized spectral count approach, with 695 of these proteins (70%) measured in at least ten subjects in the cohort (20%), with 448 proteins (45%) measured from 50% of the subjects in the cohort (Supplemental Table 3). Supplemental Fig. 1 demonstrates representative repeatability in EV isolation and protein quantification with respect to abundance. Supplemental Fig. 2 demonstrates randomly selected chromatograms versus ion currents from the study.

As expected, the most abundant proteins in the cohort were clearly enriched in proteins involved in vesicle transport, localization, and vesicle biogenesis (Fig. 3a). However, network analysis of the complete list of urinary EV proteins for tissue and biofluid enrichment shows that the kidney does not over-represent the contribution of EV proteins compared to other organs like the liver, colon, skin and brain (Fig. 3b and Supplemental Table 4). Further, restriction of the analysis to biofluid sources of proteins reveals near-equivalent percent overlap with proteins that demarcate bile, milk, saliva, and plasma fluids, with no particular enrichment of urinary proteins. These results are consistent with emerging biological data that demonstrate relatively unrestricted access for EVs in circulation in the body. As opposed to the most abundant EV proteins that are involved in vesicle biogenesis, proteins within the lower quartile of expression steeply drop off in pathway significance with nominal enrichments of proteins involved in biological processes, quality, and stimuli. Taken together, these results show that urinary EVs sample from across the body and delve deeply into the proteome to assess a diversity of biological pathways.
To determine whether there may be human disease linked proteins specifically enriched in urinary EVs (e.g., from genes linked to disease through genome-wide association studies), PANTHER classification analysis unexpectedly reveals two of the top five disease pathways with proteins linked to disease are related to neurodegenerative disorders (Fig. 3c and Supplemental Table 5). Parkinson’s disease achieves the highest enrichment (+5.1 fold, Fisher’s Exact FDR 4.5 × 10^{-7}) followed by Huntington’s disease (+4.0 fold-enrichment, Fisher’s Exact FDR 2.3 × 10^{-6}). Notably proteins identified in the enrichment of proteins linked to neurological disease includes DJ-1, ApoE, Syntaxin-7, Tyrosine-protein kinases- Yes, Lyn, FRK and HCK, proteasome subunits alpha type-7, all seven 14–3–3 protein isoforms, casein kinase I, and numerous (25 different) Rab proteins (Fig. 2Da n dE ) .

Independent pathway analysis with DAVID also highlights top links to neurological disease that includes Parkinson’s disease (2.6 fold-enrichment, p = .013 Fisher’s Exact FDR corrected) and Alzheimer’s disease (2.2 fold-enrichment, p = .009, Fisher’s Exact FDR corrected, Fig. 3d).

Broad Gene set analysis (GSEA) further reveals a prominent link to Alzheimer’s disease with 10.4% of the genes known to be downregulated in the brains from patients with Alzheimer’s disease identified in urinary EVs (Fisher’s Exact FDR corrected p = 2.2 × 10^{-11}, Supplemental Table 6).

Enrichments in neurological disease-linked proteins in the EV samples may have been caused by the inclusion of neurodegenerative disease (Parkinson’s disease) in half the discovery cohort, given the broad representation of EVs from sources likely across the body. In evaluation of the mean abundance of proteins in the PD group versus the healthy control group, SNAP23, Rab7a, calbindin, and FRK trended towards elevation in the PD group versus controls (all uncorrected p < .05, limma moderated t-tests), but were not significant after proteome-wide correction for multiple testing (one-thousand proteins). PD-linked genes range from some of the most abundant proteins (e.g., Rab10 and DJ-1) to the proteins in the lowest quartile of expression (γ-synuclein, Fig. 3e). In narrowing the analysis from one-thousand proteins to proteins identified by PANTHER analysis as linked to neurodegenerative disease, only SNAP23 survives a conservative multiple testing correction (Bonferroni, 1.8-fold elevation in PD cases, corrected p = .005, Supplemental Table 7). Overall, these results show that urinary EVs successfully capture many proteins linked to neurological disease and may be a convenient non-invasive source for proteomic biomarker discovery.

3.3. Longitudinal assessment of urinary EV proteins in biobanked samples

To date, there have been few studies to understand the variability and reliability of individual protein markers in urinary EVs since initial studies typically focus on single cross-sections of subjects that lack follow-up or repeated measures. To understand repeat variability of the urinary EV proteome defined here, two healthy control volunteers contributed weekly urine samples over the course of two months. Relative-standard deviations were calculated for the most abundant 973 proteins (identified from the 1000 proteins in the discovery
cohort). Approximately half of the proteins (41% in subject 1 and 56% in subject 2) changed in relative abundance >50% across the two months and were classified as highly variable. Several examples of both high and low abundance EV proteins demonstrate RSDs >200% (Fig. 4a).

Overall, proteins in the lower quartile of expression tend to be more variable in abundance from week to week ($\rho = -0.71$, $p < .0001$, Spearman’s $\rho$). As expected, the proteomic overlap is high between subjects with only 19 (1%) of proteins detected in one subject and not the other, with a strong correlation for individual protein variability between the two participants ($\rho = 0.58$, $p < .0001$, Spearman’s $\rho$, Fig. 4b). Analysis with DAVID and PANTHER enrichments with consideration of variability demonstrates that most of the proteins linked to neurological diseases are also among the proteins with the highest stability in levels from week to week (i.e., RSD < 50%, Supplemental Fig. 3 and Supplemental Table 8). These results demonstrate that a major fraction of proteins within urinary EVs from routine morning urine collections (non-fasting) can be very stable in relative abundance within an individual from week to week, and many of these are linked to neurological disease.

To better understand inter-individual variability of the urinary EV proteome, RSDs from the 695 EV proteins detected in most samples from the 50 subjects of the discovery cohort (Supplemental Table 1) demonstrate that only 85 proteins (~12%) varied more than two-fold in relative abundance between individuals. For the 50 EV proteins that vary the greatest between individuals in the cohort, most are highly abundant blood products in blood and are not commonly associated with EV pathways (Fig. 4c). Alpha-2-macroglobulin (RSD = 210%), ferritin light and heavy chain (RSD = 270% and 200%, respectively), complement C3 and 4A (RSD = 180% and 160%), and different hemoglobin subunits (alpha, beta and delta hemoglobin, RSD = 140%, 160% and 160%), are all well-known blood products that are extremely variable in urinary EV fractions between individuals and within the same individual over time. Importantly, all samples showed normal urinalysis that was negative for the presence of red-blood cells. Past whole-urine proteome studies have suggested that high abundant proteins in blood can be filtered in the kidney and secreted through a poorly understood pathway by tubular cells under certain conditions [41].

Besides the extremely variable EV proteins that tend to be blood products, we identified proteins with the lowest variability across participants that may be classified as housekeeping proteins. These include numerous heat shock proteins (RSD = 14–19%), actin (RSD = 21%), and annexin A4 (RSD = 22%) (Fig. 4c). These proteins may be useful for normalization across different groups and in longitudinal studies since they vary little from week to week in the same individual as well as across different groups of individuals.

3.4. Identification of proteins in EVs driven by THP contamination

In the purification of heterogenous EVs from biofluids such as plasma or serum, co-contaminating proteins with affinity towards lipids...
and vesicles such as lipoproteins and immunoglobulins can deleteriously affect unbiased capture of the EV population through loss of the EVs during purification. While urine does not contain abundant lipoproteins or albumins, the most abundant protein contaminating the EV preparations was identified as uromodulin (THP, or Tamm-Horsfall protein, Fig. 4c). THP is secreted by the loop of Henle in the kidney and may have anti-bacterial and anti-calcium crystallization properties, present at 21.3 ± 1.2 mg per day in males and 15.2 ± 1.6 mg per day in females [42]. THP is a non-EV associated secreted glycoprotein that is exclusively produced by renal tubular cells [43,44]. During the urine EV isolation process, THP readily fibrilizes into aggregates that can entrap some EVs at low speed centrifugation, with a small portion of THP fibrils of higher molecular weight co-eluting in EV enriched fractions at high speed centrifugation in different forms (Supplemental Fig. 4) [45].

Some recent data suggest that THP fibril contamination may interact with EVs to skew EV recovery and confound analysis [22,44]. Side-by-side comparison of the proteome of samples from the discovery cohort with lower THP contamination versus those with the highest THP contamination via Coomassie analysis of samples did not show an obvious reduction in the banding of other abundant EV proteins (Fig. 5a). THP levels determined by mass spectrometry are similar between PD and control groups (Fig. 5b, \( p = .24 \), 2-sided t-test) and overall the abundance of most proteins in the fifty participants (>92% of the thousand evaluated) is not correlated with the abundance of THP (Fig. 5c). Proteins with the strongest negative correlation with THP in abundant EV proteins include annexinVI, Rab8, and Rab5 (\( p < .05 \), FDR corrected, Supplemental Table 9). Cross-evaluation of PANTHER pathways assigned to proteins with the strongest negative correlation with THP in abundant EVs to skew EV recovery and confound analysis [22,44].

3.5. Candidate urinary EV biomarkers for Parkinson's disease

From the discovery cohort of samples evaluated by bottom-up shotgun proteomics (Fig. 2), 15 urinary EV proteins were identified that were relatively stable over time within individuals (RSD < 100% from week to week, Fig. 4c) that could be measured in at least 50% of the cases and controls and were different in mean abundance in PD versus healthy controls (limma moderated t statistics for this subset of proteins were calculated for each candidate, Fig. 3, Supplemental Table 7). Receiver operator characteristics (ROC) and areas under the curve (AUC) range from 0.66 to 0.8 for each of these candidates (Supplemental Table 7). The best performing protein in separating PD from control, SNAP23 (\( p = .0009 \), AUC = 0.80, ROC), demonstrates 70% sensitivity and 80% specificity in ROC analysis on its own, whereas the next best protein calbindin (\( p = .004 \), AUC = 0.75, ROC) has 76% sensitivity and...
71% specificity (Fig. 6a,b). Logistic regression suggests the linear combination of SNAP23 and calbindin may improve the characteristics to an AUC of 0.86 with 77% sensitive and 85% specificity (Fig. 6c).

To evaluate the SNAP23 and calbindin pair using an orthogonal protein quantification method in an independent cohort of bio banked urine samples, we developed a traditional immunoblot assay using validated monoclonal antibodies to SNAP23 and calbindin, with heat-shock protein 70 (HSC70/HSPA8) identified as an appropriate housekeeping control that is highly stable and is not different in PD versus control (Fig. 4b, Supplemental Figs. 5 and 6). Other commonly known EV markers (TSG101, CD9, CD81, Annexin A5) are equivalent between PD and control groups, whereas CD63, Flotillin-1 and Flotillin-2, although not identified as significant using limma moderated t-tests in the proteomic data, are higher in PD compared to controls (Supplemental Fig. 7). Initial evaluation of the same protein lysates used for mass spectrometry with the immunoblot analysis demonstrates good but not perfect correlation in results between the two assays ($p = 0.80$ and $p = 0.72$ for SNAP23 and calbindin, respectively, Spearman’s $\rho$, Supplemental Fig. 5). Application of the immunoblot assay to a replication cohort of participants that include 51 idiopathic PD patients (28 male and 23 female) and 57 age matched controls (28 male and 29 female) likewise shows elevated calbindin in PD ($p \leq 0.0001$, AUC = 0.75, ROC, Fig. 7a and b). Four samples were excluded where calbindin was not detected. SNAP23 was more difficult to detect in the replication cohort with undetectable levels in 32 out of 108 individuals. Of the 31 samples with very low SNAP23 levels, 20 of them (75%) come from the control group, whereas 8 with PD are below detection levels. Combination of calbindin and SNAP23 in the same logistic model demonstrates similar efficacy in prediction of the diagnosis of PD (AUC = 0.76, ROC, Fig. 7c) as the initial mass spectrometry analysis, with 71% sensitive and 69% overall specificity. Spearman correlation values calculated for each demographic or clinical measure collected did not reveal any potential co-variables that might be affecting protein levels, including sex, dopamine medications, or duration of disease (all $p > 0.5$, Spearman’s $\rho$). These results suggest urinary SNAP23 and calbindin may contribute to a useful biomarker panel for PD. More broadly, this study has identified the subset of proteins that are the most stable and reliably detected in clinical populations that may serve as ideal biomarkers for neurological diseases, as well as contaminating proteins and highly variable proteins inherent to the preparations that are unlikely to serve as useful biomarkers.

4. Discussion

As a source for novel biomarkers, EVs contain proteins not usually accessible for measure without tissue biopsies. However, EVs are in low abundance in bio fluids thereby presenting detection challenges. Further, the half-life, variability of turn-over, and heterogeneity of vesicle sources in the body are all factors that are poorly understood, especially in clinical populations. In contrast to blood, serum, cerebrospinal fluid (CSF), and saliva, urine can be obtained non-invasively and in higher abundance than other biofluids, enabling proteomic analyses with a range of existing technology. To date, studies in urine biomarkers have focused on kidney and metastatic cancers due to the presumptive source of urinary EVs, the kidney. Here, we demonstrate that urine EVs are more heterogeneous than previously supposed by using advanced imaging approaches in specimens from a broad clinical population. Enrichment analyses show that the EV proteome harbors proteins that demarcate organs across the body without enrichment of kidney proteins. Our data suggest that most urinary EV proteins are stable within individuals over time, a sought-after property for biomarker discovery and utility. Among the stable proteins detected in most specimens from a biobanked clinical cohort, proteins linked to neurodegenerative diseases are enriched in the urinary EV proteome. Shotgun proteomics from the initial discovery cohort identified SNAP23 and calbindin as elevated in PD, with a replication cohort and orthogonal immunoblot detection assay validating the increased levels of SNAP23 and calbindin that occur in most PD patients. Overall, given the stable characteristics and positive case study with PD patients in initial biomarker candidate selection, these results provide evidence that urinary EVs may be an underutilized resource, with pathway analysis implicating particular utility in neurological diseases.

Extracellular vesicles (EVs) are secreted by most if not all cell types into biofluids. Differential ultracentrifugation is commonly used to capture the whole population of vesicles at the size range 40 nm–200 nm, including exosomes derived from endosomal pathway and other membrane-derived vesicles at similar size [2,19,20,46]. Here, we characterize urine EVs using single particle tracking and cryo-EM. Although the medium size EVs (100–150 nm) are more common compare to small size vesicles generally classified as small EVs (30–70 nm), we also identified large EVs (>200 nm) with variable morphology. Although single-vesicle particle analysis has not yet been achieved, future enrichment approaches may begin to unravel the striking heterogeneity.

While several studies have evaluated the proteome of urinary EVs, there are no previous datasets we are aware of that examine the stability over time and variability of expression of individual EV proteins in clinical populations [25,47,48]. Our study identified hundreds of proteins that appear quite stable, at least over several weeks in healthy individuals, as well as those proteins that are highly variable both between individuals and within individuals from week to week. Within the stable pool of proteins that vary little over time and can be measured in most individuals, we identified robust enrichments of proteins linked to neurological diseases. While future studies are required to identify
the source of different EVs that contribute these disease-linked proteins to the overall EV pool, based on tissue enrichment analysis, it is conceivable that urinary EVs derive from organs across the body, including the brain. Tracking experiments in model organisms would provide valuable information in this regard.

Although we did not identify any urinary EV proteins that were only in the PD group and not control group, or vice versa, we reasoned that valuable biomarkers for PD may nevertheless exist in the EV pool based on the clear disease-enrichments observed in several bioinformatics analyses. Biomarkers identified from whole proteomic or transcriptomic data using multiple comparisons from single cross-sectional cohorts with one analytical technique are typically confounded by data overfitting (e.g., linear models) and high false-positive rates. Here, we identified a biobanked replication cohort approximately twice the size of the discovery cohort to test a limited number of the best performing biomarkers, SNAP23 and calbindin, using an independent measurement assay [49]. Our orthogonal immunoblotting assay was clearly less sensitive at detecting SNAP23 and calbindin in the samples, with successful detection dropping from 86% in the discovery cohort to 73% in the replication cohort for SNAP23. Nevertheless, the two proteins performed similarly in separating PD from control in the replication cohort, warranting further exploration of these markers.

We failed to identify any correlated variables for SNAP23 and calbindin from all clinical and demographic data collected including age, sex, medication use, or clinical severity of disease. Synaptosomal-associated protein 23 (SNAP23) is a component of the SNARE complex with 58% identity to SNAP25 with function in exocytosis in neurons [50,51]. Whereas SNAP25 is mainly expressed in the brain, SNAP23 is ubiquitously expressed. A recent study found increased SNAP25 in CSF from PD patients, and depletion of SNAP25 in PD post-mortem brain [52]. Genetic polymorphisms in SNAP25 have also been linked to PD severity [53]. There are nuanced differences between SNAP23 which can compete with SNAP25 in supporting neurotransmitter release and vesicle fusion but not in vesicle pool priming [54]. In contrast, calbindin (CALB1) is a type of calcium binding protein important for calcium buffering and is vitamin D responsive in many tissues. It is highly expressed in kidney and brain, and may be depleted in Alzheimer’s, Huntington’s and Parkinson’s disease patients [55–57]. Calbindin knockout aggravated Alzheimer’s phenotypes in mouse models [55]. Recent studies further found that Lewy bodies are observed mostly in calbindin-negative neurons in patients with dementia with Lewy bodies (DBL) [58]. While both proteins can be connected to neurodegenerative disease, the discovery of their stable presence in urinary EVs presents an opportunity to better understand their role in both health and disease. Important for future studies will be determining whether their differential abundance in PD represents traits that increase susceptibility to disease or states that are responsive to disease progression. The lack of correlation of their levels to drug dose or disease duration in PD cases provides evidence for susceptibility factors stable in time versus disease states that are variable over time.

While this study evaluated hundreds of EV proteins in over 100 subjects, our measures likely represent the tip of the iceberg in information that can be extracted from urinary EVs. Our peptide analysis did not include measurements of important post-translational modifications like phosphorylation or ubiquitination. For example, our recent studies found dramatic differences in pS1292-LRRK2 autophosphorylation levels using phospho-specific antibodies in urinary EVs from LRRK2-mutation carriers in PD [59–61]. Our studies here should facilitate more directed future studies with our identification of the most stable proteins that vary little over time and between individuals as housekeeping proteins, as well as the total levels of hundreds of other proteins in a cross-section of subjects. In sum, our results suggest that urinary EVs may be an underutilized resource that could be considered for biomarker discovery to address a variety of unmet needs in precision medicine approaches.

Acknowledgments

Data and biospecimens used in preparation of this manuscript were obtained from the Parkinson’s Disease Biomarkers Program (PDBP) Consortium, part of the National Institute of Neurological Disorders and Stroke at the National Institutes of Health. Investigators include: Roger Albin, Roy Alcalay, Alberto Ascherio, Brad Boeve, DuBois Bowman, Alice Chen-Plotkin, Ted Dawson, Richard Dewey, Kirk Frey, Dwight German, Lawrence Honig, Xuemei Huang, Kejal Kantarci, Jim Leverenz, Karen Marder, Rachel Saunders-Pullman, Liana Rosenthal, Clemens Scherzer, Michael Schwarzschild, David Vaillancourt, David Walt, Andrew West and Jing Zhang. The PDBP Investigators have not participated in reviewing the data analysis or content of the manuscript.

The authors appreciate Dr. Kyle Fraser’s help for preparing the samples for mass spectrometry. We appreciate Dr. Richard Kennedy’s suggestions for statistical analysis and help on performing limma moderated t-tests.

We acknowledge core resources provided by the UAB Comprehensive Cancer Center, UAB Institutional Core Funding Mechanism, and core resources made possible through NCI P30 CA013148.

Funding sources

Research support was provided by NIH/NINDS U01 NS097028 and R01 NS064934.
The funding sources had no role in writing the manuscript or decision to submit the manuscript for publication. The authors have not had full access to all the data and assumes final responsibility for the decision to submit for publication.

Declaration of interests

The authors have no conflicting interests to declare.

Author contributions

S.W., K.K., J.A.M., and A.B.W. performed literature searches, designed studies, collected data, interpreted data, and wrote the paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2019.06.021.

References

[1] Fevrier B, Vilette D, Archer F, Loew D, Faigle W, Vidal M, et al. Cells release prions in association with exosomes. Proc Natl Acad Sci U S A 2004;101(26):9683–8.
[2] Harding CV, Heuser JE, Stahl PD. Exosomes: looking back three decades and into the future. J Cell Biol 2013;200(4):367–71.
[3] Ngolab J, Trinh I, Rockenstein E, Mante M, Florio J, Trejo M, et al. Brain-derived exosomes from dementia with Lewy bodies potentiate alpha-synuclein pathology. Acta Neuropathol Commun 2017;5(1):46.
[4] Dieude M, Bell C, Turgeon J, Beillevaire D, Pomerleau Y, Bang Y, et al. The 20s proteome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. Sci Transl Med 2015;7(318):318ra200.
[5] Prunotto M, Farina A, Lane L, Pernin A, Schifferli J, Hochstrasser DF, et al. Proteomic characterization of urinary nanovesicles following CHAPS treatment. PLoS One 2012;7(10):e47279.
[6] Balusu S, Van Wonterghem E, De Rycke R, Raemdonck K, Stremersch S, Gevaert K, et al. Evaluation of the urinary exosome proteome and phosphoproteome of urinary exosomes. J Am Soc Nephrol 2009;20(6):1220–8.
[7] Zomer A, Maynard C, Kolker E, Aebersold R. Empirical statistical model to estimate relative protein abundance in shotgun proteomics. Anal Chem 2004;76(14):4647–56.
[8] Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 2005;4(10):1487–502.
[9] Hoorn EJ, Pisitkun T, Zietse R, Gross P, Frokiaer J, Wang NS, et al. Prospects for urinary exosome-based biomarkers: a system biology approach. Nephrol Dial Transplant 2000;15(10):1580–7.
[10] Kunii M, Ohara-Imaizumi M, Takahashi N, Kobayashi M, Kawakami R, Kondoh Y, et al. Protein complexes in urine interfere with extracellular vesicle biomarker studies. J Proteome Res 2014;13(3):1502–14.
[11] Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002;74(20):5381–92.
[12] Prunotto M, Farina A, Lane L, Pernin A, Schifferli J, Hochstrasser DF, et al. Proteomic characterization of urinary nanovesicles following CHAPS treatment. PLoS One 2012;7(10):e47279.
[13] Glauser A, Hochreiter W, Jaeger P, Hess B. Determinants of urinary excretion of beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A 2006;103(30):11172–7.
[14] Reiner J, Sturk A, Nieuwland R. Classification, functions, and potential applications of urinary extracellular vesicles. J Mol Cell Proteomics 2015;14(10):1548–9.
[15] Kunii M, Ohara-Imaizumi M, Takahashi N, Kobayashi M, Kawakami R, Kondoh Y, et al. Protein complexes in urine interfere with extracellular vesicle biomarker studies. J Proteome Res 2014;13(3):1502–14.
[16] Hoorn EJ, Pisitkun T, Zietse R, Gross P, Frokiaer J, Wang NS, et al. Prospects for urinary exosome-based biomarkers: a system biology approach. Nephrol Dial Transplant 2000;15(10):1580–7.
[17] Prunotto M, Farina A, Lane L, Pernin A, Schifferli J, Hochstrasser DF, et al. Proteomic analysis of podocyte exosome-enriched fraction from normal human urine. J Proteom Res 2015;14(1):503–11.
[18] Klimis-Zacas D, Chantry D, Vlahos R, et al. Urinary exosomes reveal protein signatures in hypertensive patients. Nephrol Dial Transplant 2000;15(10):1580–7.
[19] Prunotto M, Farina A, Lane L, Pernin A, Schifferli J, Hochstrasser DF, et al. Proteomic analysis of podocyte exosome-enriched fraction from normal human urine. J Proteom Res 2015;14(1):503–11.
[20] Shi M, Liu C, Cook TJ, Bullock KM, Zhao Y, Ginchina C, et al. Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol 2014;128(5):639–50.
[21] Wang D, Sun W. Urinary extracellular microvesicles: isolation methods and prospects for urinary proteomics. J Proteomes 2014;14(16):1922–32.
[22] Musante L, Tataruch DE, Hohlhoefer H. Use and isolation of urinary exosomes as biomarkers for diabetic nephropathy. Front Endocrinol (Lausanne) 2014;5:149.
[23] Wood SL, Knowles MA, Thompson D, Selby PJ, Banks RE. Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nat Rev Urol 2013;10(12):654–6.
[24] Boudieroux M, Nguyen-Khoa T, Chhuon C, Jeanlou L, Tondelier D, Walczak M, et al. A new workflow for proteome analysis of urinary exosomes and assessment in cystinuria patients. J Proteome Res 2015;14(1):567–77.
[25] Derij H, Street JM, Bailey MA. Urinary exosomes: a reservoir for biomarker discovery and potential developers of intranarial signaling. Proteomics 2013;13(10–11):1572–80.
[26] Hildonen S, Skarpen E, Halvorsen TC, Reubsaet L and mass spectrometry analysis of urinary extracellular proteins. Sci Rep 2016;6:36331.
[27] Prunotto M, Farina A, Lane L, Pernin A, Schifferli J, Hochstrasser DF, et al. Proteomic analysis of podocyte exosome-enriched fraction from normal human urine. J Proteom Res 2015;14(1):503–11.
[28] Prunotto M, Farina A, Lane L, Pernin A, Schifferli J, Hochstrasser DF, et al. Proteomic analysis of podocyte exosome-enriched fraction from normal human urine. J Proteom Res 2015;14(1):503–11.
[29] Shi M, Movius J, Dator R, Aro P, Zhao Y, Pan C, et al. Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Mol Cell Proteomics 2015;14(3):544–55.
[30] Kunii M, Ohara-Imaizumi M, Takahashi N, Kobayashi M, Kawakami R, Kondoh Y, et al. Opposing roles for SNP23 in secretion in exocrine and endocrine pancreatic cells. J Cell Biol 2016;215(1):121–38.
[31] Ravichandran V, Chavala A, Roche PA. Identification of a novel syntaxin- and synaptobrevin/VAMP-binding protein, SNAP-23, expressed in non-neuronal tissues. J Biol Chem 1996;271(23):13300–3.
[32] Borrego E, Bogsted A, Högland K, Titati P, Brendin L, Ballard C, et al. Synaptic proteins in CSF relate to Parkinson’s disease stage markers. NPJ Parkinsons Dis 2017;3:7.
[53] Agliardi C, Guerini FR, Zanzottera M, Riboldazzi G, Zangaglia R, Sturchio A, et al. SNAP25 gene polymorphisms protect against Parkinson's disease and modulate disease severity in patients. Mol Neurobiol 2019;56(6):4455–63.

[54] Sorensen JB, Nagy G, Varoqueaux F, Nehring RB, Brose N, Wilson MC, et al. Differential control of the releasable vesicle pools by SNAP-25 splice variants and SNAP-23. Cell 2003;114(1):75–86.

[55] Kook SY, Jeong H, Kang MJ, Park R, Shin HJ, Han SH, et al. Crucial role of calbindin-D28k in the pathogenesis of Alzheimer's disease mouse model. Cell Death Differ 2014;21(10):1575–87.

[56] You JC, Muralidharan K, Park JW, Pyfer MS, Corbett BF, et al. Epigenetic suppression of hippocampal calbindin-D28k by DeltaFosB drives seizure-related cognitive deficits. Nat Med 2017;23(11):1377–83.

[57] Iacopino AM, Christakos S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci U S A 1990;87(11):4078–82.

[58] Rcom-H'cheo-Gauthier AN, Davis A, Meedeniya ACB, Pountney DL. Alpha-synuclein aggregates are excluded from calbindin-D28k-positive neurons in dementia with Lewy bodies and a unilateral rotenone mouse model. Mol Cell Neurosci 2016;77:65–75.

[59] Fraser KB, Moeble MS, Alcalay RN, west AB, consortium LC. Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. Neurology 2016;86(11):994–9.

[60] Fraser KB, Rawlins AB, Clark RG, Alcalay RN, Standaert DG, Liu N, et al. Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. Mov Disord 2016;31(10):1543–50.

[61] Wang S, Liu Z, Ye T, Mahbouk OS, Malthie T, Aasly J, et al. Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers. Acta Neuropathol Commun 2017;5(1):86.